Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 8/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17050432 | 0.79 | ACACB (0.41) | NPC1RAB9ATLR8TLR7ACACB | |
| SCHEMBL17050426 | 0.79 | RAB9A (0.41) | NPC1GAAMAPK1RAB9ATLR8 | |
| SCHEMBL21631583 | 0.78 | NPC1 (0.42) | NPC1GAAMAPK1RAB9ATLR8 | |
| SCHEMBL14684249 | 0.77 | RAB9A (0.56) | NPC1GAAMAPK1RAB9ATLR8 | |
| SCHEMBL24199111 | 0.76 | NPC1 (0.43) | NPC1GAAMAPK1RAB9ATLR8 | |
| SCHEMBL17050425 | 0.75 | ACACB (0.35) | ACACBCYP2C9ACACA | |
| SCHEMBL17050427 | 0.74 | ACACB (0.36) | ACACBCYP2C9ACACA | |
| SCHEMBL13824618 | 0.70 | PSMB8 (0.51) | NPC1GAAMAPK1RAB9ATLR8 | |
| SCHEMBL16716025 | 0.69 | RAB9A (0.51) | NPC1GAAMAPK1RAB9ATLR8 | |
| SCHEMBL21653722 | 0.69 | NPC1 (0.34) | NPC1GAAMAPK1RAB9ATLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | ACSS2, ACACB, ACAT2 | NPC1 1419/4885GAA 2309/4885MAPK1 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.